BiotechTube
Attovia Therapeutics

Attovia Therapeutics

Fremont, United States· Est.
attovia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $262M

Overview

Attovia Therapeutics is an early-stage, private biotech leveraging its proprietary ATTOBODY™ platform to develop first-in-class multispecific biologics for immune-mediated inflammatory diseases (I&I). The company aims to overcome the limitations of single-pathway treatments by designing drugs that engage multiple targets, potentially offering superior efficacy for patients who remain undertreated. Led by a team of veteran drug developers, Attovia is building a pipeline of precision biologics and is actively seeking partnerships to advance its platform and programs.

Immune-mediated Inflammatory Diseases

Technology Platform

Proprietary ATTOBODY™ platform, a modular protein design platform for creating novel multispecific biologics that engage multiple disease pathways.

Funding History

4
Total raised:$262M
Series C$90M
Series B$105M
Series A$60M
Seed$7M

Opportunities

The large and growing market for immune-mediated diseases, combined with significant unmet need in patient subpopulations refractory to current therapies, presents a major opportunity.
Successfully leveraging the ATTOBODY™ platform to create first-in-class multispecifics could enable Attovia to capture value in multi-billion dollar therapeutic areas and attract partnership interest from large pharma.

Risk Factors

Key risks include platform validation risk, as the ATTOBODY technology is unproven in clinical development; intense competition in the multispecific antibody space from larger, well-funded entities; and financial dependency on venture capital in a challenging funding environment.

Competitive Landscape

Attovia operates in the highly competitive field of multispecific biologics for immunology, competing against large biopharma companies (e.g., Amgen, Roche, AbbVie) with established platforms and numerous agile biotech startups. Differentiation will require demonstrating superior molecule properties, novel biology, or best-in-class efficacy in the clinic.

More companies in Biologics / Biosimilars →More companies in United States →